Last reviewed · How we verify
RO7234292
RO7234292 is a monoclonal antibody that targets and inhibits Claudin 18.2 (CLDN18.2), a tumor-associated antigen expressed on gastric and other cancer cells.
RO7234292 is a monoclonal antibody that targets and inhibits Claudin 18.2 (CLDN18.2), a tumor-associated antigen expressed on gastric and other cancer cells. Used for Gastric cancer (gastric adenocarcinoma), Gastroesophageal junction cancer.
At a glance
| Generic name | RO7234292 |
|---|---|
| Also known as | Tominersen |
| Sponsor | Hoffmann-La Roche |
| Drug class | Monoclonal antibody (CLDN18.2-targeting) |
| Target | Claudin 18.2 (CLDN18.2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CLDN18.2 is a tight junction protein aberrantly expressed on the surface of gastric cancer and other malignancies. By binding to CLDN18.2, RO7234292 triggers antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), leading to direct tumor cell killing. This mechanism allows the immune system to recognize and eliminate cancer cells expressing this antigen.
Approved indications
- Gastric cancer (gastric adenocarcinoma)
- Gastroesophageal junction cancer
Common side effects
- Infusion-related reactions
- Nausea
- Vomiting
- Fatigue
- Diarrhea
Key clinical trials
- GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease (PHASE2)
- A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease (PHASE3)
- An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies (PHASE3)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO7234292 CI brief — competitive landscape report
- RO7234292 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI